Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CTXR

Citius Pharmaceuticals Inc

May 21 • 03:00PM ET

0.7310

Dollar change +0.0712
Percentage change 10.79	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV URTY VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.24	Insider Own	7.74%	Shs Outstand	180.67M	Perf Week	6.31%
Market Cap	132.07M	Forward P/E	73.10	EPS next Y	0.01	Insider Trans	0.00%	Shs Float	166.70M	Perf Month	-0.44%
Income	-37.35M	PEG	-	EPS next Q	-0.06	Inst Own	15.05%	Short Float	8.66%	Perf Quarter	-5.05%
Sales	0.00M	P/S	-	EPS this Y	0.00%	Inst Trans	-6.74%	Short Ratio	14.80	Perf Half Y	-5.42%
Book/sh	0.50	P/B	1.47	EPS next Y	104.55%	ROA	-37.14%	Short Interest	14.43M	Perf Year	-38.05%
Cash/sh	0.07	P/C	10.52	EPS next 5Y	-	ROE	-42.44%	52W Range	0.60 - 1.40	Perf YTD	-3.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.21%	ROI	-46.97%	52W High	-47.79%	Beta	1.60
Dividend TTM	-	Quick Ratio	5.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.83%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	5.17	EPS Y/Y TTM	-11.75%	Oper. Margin	0.00%	RSI (14)	52.08	Volatility	6.80% 7.70%
Employees	22	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	25.42%	Payout	-	Rel Volume	23.60	Prev Close	0.66
Sales Surprise	-	EPS Surprise	9.09%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	974.83K	Price	0.73
SMA20	5.31%	SMA50	-4.85%	SMA200	-4.87%	Trades		Volume	19,641,581	Change	10.79%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-30-21	Initiated	Maxim Group	Buy	$4

Today 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.79%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%
08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
Apr-11-24 08:30AM	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma (PR Newswire)
Apr-04-24 08:30AM	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference (PR Newswire)
Mar-18-24 08:30AM	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-07-24 08:30AM	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program (PR Newswire)
07:30AM	Loading…
Feb-26-24 07:30AM	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration (PR Newswire)
Feb-23-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences (PR Newswire)
Feb-15-24 09:17AM	Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials (GuruFocus.com) +9.12%
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire) +13.51%
08:01AM	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jan-23-24 08:30AM	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors (PR Newswire)
Jan-02-24 08:31AM	Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters (PR Newswire) +6.90%
08:30AM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 08:30AM	Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 (PR Newswire)
Oct-31-23 08:45AM	Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor (PR Newswire)
Oct-24-23 07:30AM	Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire) +17.36%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:30PM	Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 (PR Newswire)
Sep-13-23 04:30PM	Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir (PR Newswire) -6.48%
08:00AM	Loading…
Sep-08-23 08:00AM	Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR (PR Newswire)
Sep-06-23 04:30PM	Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 (PR Newswire) -5.25%
Aug-14-23 04:15PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-10-23 08:37AM	Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial (PR Newswire) +8.20%
Jul-29-23 04:16PM	Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jun-26-23 08:30AM	Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes (PR Newswire) +5.43%
Jun-20-23 04:09PM	Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In Symptoms (Benzinga)
08:30AM	Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids (PR Newswire)
Jun-13-23 08:30AM	Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 (PR Newswire)
May-12-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire) +6.82%
May-08-23 01:42PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire)
May-04-23 08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire) -16.11%
Apr-24-23 09:10AM	Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date (PR Newswire)
Apr-03-23 08:00AM	Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire) +14.53%
Mar-30-23 08:30AM	Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company (PR Newswire) +6.36%
Mar-27-23 09:52AM	When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? (Simply Wall St.)
Mar-13-23 09:15AM	Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank (PR Newswire) -5.61%
Mar-08-23 08:30AM	Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference (PR Newswire)
Feb-10-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-06-23 10:30AM	Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks (TheStreet.com)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-16-23 07:09AM	Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation (Simply Wall St.)
Jan-11-23 08:30AM	Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 (PR Newswire) +7.10%
Dec-28-22 09:35AM	After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR) (Zacks)
Dec-22-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
Dec-01-22 07:30AM	Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire) +5.13%
Nov-21-22 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program (PR Newswire)
Nov-09-22 08:30AM	Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Oct-18-22 08:30AM	Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 (PR Newswire)
07:59AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook (Simply Wall St.)
Oct-06-22 04:30PM	Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 (PR Newswire)
Sep-28-22 08:30AM	Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire)
Sep-23-22 06:48AM	Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings (Benzinga)
Sep-22-22 04:30PM	Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial (PR Newswire)
Sep-15-22 08:30AM	Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute (PR Newswire)
Sep-08-22 04:30PM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) +6.40%
Sep-07-22 08:30AM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-11-22 04:31PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire) +13.33%
Aug-09-22 07:24AM	Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely (Simply Wall St.) -7.77%
Jul-12-22 08:07AM	Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
May-25-22 10:13AM	Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm (Benzinga)
08:47AM	Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company (PR Newswire)
May-18-22 09:30AM	Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 (PR Newswire)
May-12-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-11-22 07:34AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit (Simply Wall St.) -13.48%
May-10-22 11:10AM	10 Penny Stocks to Buy in May (Insider Monkey) +8.31%
May-08-22 09:00AM	3 Reddit Stocks to Buy in May (InvestorPlace)
May-06-22 09:37AM	Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally (PR Newswire) +6.86%
May-03-22 10:06AM	Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones (PR Newswire) +6.33%
Apr-26-22 08:30AM	Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire)
Apr-14-22 09:25AM	Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022 (PR Newswire)
Apr-13-22 09:25AM	Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates (PR Newswire)
Apr-07-22 09:57AM	Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study (Zacks) -8.19%
Apr-06-22 08:14AM	Shares of Citius jump 18% on new data for experimental lymphoma drug (MarketWatch) -7.07%
06:50AM	Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission (PR Newswire)
Mar-29-22 10:18AM	These 10 Penny Stocks are Trending on Reddit (Insider Monkey)
Mar-03-22 09:15AM	Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences (PR Newswire)
Mar-02-22 04:12AM	Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Invest In Growth? (Simply Wall St.)
Feb-15-22 09:15AM	Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire) +5.84%
Feb-10-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Jan-04-22 09:00AM	Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences (PR Newswire)
Dec-15-21 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update (PR Newswire)
Dec-06-21 09:15AM	Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) +7.95%
Dec-02-21 05:17AM	Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) (Simply Wall St.)
Nov-05-21 09:15AM	Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (PR Newswire)
Oct-25-21 09:15AM	Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients (PR Newswire)
Oct-13-21 11:38AM	Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777) (PR Newswire)
Oct-06-21 10:40AM	Citius Pharmaceuticals to Present at Upcoming October Investor Conferences (PR Newswire)
Oct-04-21 12:31PM	10 Reddits WallStreetBets Stocks Under $5 (Insider Monkey)
Oct-01-21 08:30AM	Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur (PR Newswire)

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your FINVIZ experience